Line of Credit 
Print FormatVaxart to Present at World Vaccine Congress Washington 2022 on April 20
The title of Dr. Tucker’s presentation is “Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination.” Dr. Tucker will discuss data supporting the potential benefits of Vaxart’s oral tablet COVID-19 vaccine candidate, which is in clinical development.
About Vaxart (VXRT)
Vaxart (VXRT) is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart (VXRT) vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart (VXRT) believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart (VXRT) has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contacts
| Vaxart Media Relations: | Investor Relations: |
| Mark Herr | |
| Vaxart, Inc. (VXRT) | FINN Partners |
| mherr@vaxart.com | IR@Vaxart.com |
| (203) 517-8957 | (646) 871-8486 |
Image: https://ml.globenewswire.com/media/OGEzNzY2MDItNjZmNy00NGY1LWEzYWYtM2Y0ZWJjNTA0ZWFjLTEwMzA2ODI=/tiny/Vaxart-Inc-.png
Image: Primary Logo
Source: Vaxart, Inc. (VXRT)
